Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Cytokinetics, Inc.    CYTK   US23282W1009

CYTOKINETICS, INC. (CYTK)

8
End-of-day quote. End-of-day quote Nasdaq - 06/25
12.05 USD   -2.03%
07/16 CYTOKINETICS : to Announce Second Quarter Results on July 30, 2014
07/15 CYTOKINETICS : Assigned Patent
07/10 CYTOKINETICS : Other Events (form 8-K)
SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Cytokinetics, Inc. : Cytokinetics, Incorporated Receives NASDAQ Notice of Minimum Bid Price Compliance

01/25/2013 | 04:24pm US/Eastern
Recommend:
0
Cytokinetics, Incorporated Receives NASDAQ Notice of Minimum Bid Price Compliance

South San Francisco, CA - January 25, 2013

Cytokinetics, Incorporated (NASDAQ: CYTK), announced today that it has received a notice from The Nasdaq Stock Market ("Nasdaq") confirming that for the last 10 consecutive business days, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with the minimum $1.00 bid price per share requirement.

As previously reported, the Company received notice from Nasdaq on June 18, 2012 that the Company's common stock had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. On December 18, 2012, the Company transferred its listing to the Nasdaq Capital Market and Nasdaq provided the Company until June 17, 2013 to achieve compliance with the minimum $1.00 bid price per share requirement.

Nasdaq has informed the Company that this matter is now closed.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing tirasemtiv, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. All of these drug candidates have arisen from Cytokinetics' muscle biology focused research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

distributed by
Recommend :
0
React to this article
Latest news on CYTOKINETICS, INC.
07/16 CYTOKINETICS : to Announce Second Quarter Results on July 30, 2014
07/15 CYTOKINETICS : Assigned Patent
07/10 CYTOKINETICS : Other Events (form 8-K)
07/10 CYTOKINETICS : Announced Additional Results Relating to Tirasemtiv from Pre-Spec..
07/03 CYTOKINETICS : Announces Additional Data from BENEFIT-ALS to be Presented at the..
06/30 CYTOKINETICS : Assigned Patent
06/13 CYTOKINETICS : Announces Data Relating to Tirasemtiv Presented at the 2014 Annua..
06/13 CYTOKINETICS : Other Events (form 8-K)
06/06 CYTOKINETICS : Announces Two Presentations Relating to Tirasemtiv to be Presente..
06/02 CYTOKINETICS : Other Events (form 8-K)
Advertisement
Chart
Duration : Period :
Cytokinetics, Inc. Technical Analysis Chart | CYTK | US23282W1009 | 4-Traders
Income Statement Evolution
Cytokinetics, Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF